Actavis Q1 Beats Estimates, Includes Allergan In 2015 Guidance

By | May 11, 2015

Scalper1 News

Specialty-drug giant and IBD 50 stock Actavis (ACT) beat Wall Street’s Q1 estimates Monday and for the first time offered 2015 guidance, including the newly acquired Allergan, which was in line with expectations. Actavis stock was up 3% in early trading Monday and moved above its 10-week moving average. The company said earnings in the quarter rose 23% over the year-earlier quarter to $4.30 a share, 37 cents above analysts’ consensus, according to Scalper1 News

Scalper1 News